Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation.
CTLA-4-deficient mice develop a lethal autoimmune lymphoproliferative disorder that is strictly dependent on in vivo CD28 costimulation. Nevertheless, it is not known whether there is a specific site on the CD28 molecule that is required for induction of autoimmunity. Using CTLA-4-deficient mice expressing CD28 molecules with various point mutations in the CD28 cytosolic tail, the present study documents that in vivo costimulation for induction of autoimmune disease strictly requires an intact C-terminal proline motif that promotes lymphocyte-specific protein tyrosine kinase Lck binding to the CD28 cytosolic tail, because point mutations in C-terminal proline residues (Pro-187 and Pro-190) completely prevented disease induction. In contrast, in vivo costimulation for disease induction did not require either an intact YMNM motif or an intact N-terminal proline motif, which, respectively, promote phosphoinositide 3-kinase and IL2-inducible T cell kinase binding to the CD28 cytosolic tail. Thus, in vivo CD28 costimulation for induction of autoimmune disease is strictly and specifically dependent on an intact C-terminal proline motif that serves as a lymphocyte-specific protein tyrosine Lck kinase binding site in the CD28 cytosolic tail.
Tai
Xuguang
X
Experimental Immunology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Van Laethem
Francois
F
Sharpe
Arlene H
AH
Singer
Alfred
A
D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism; D000595:Amino Acid Sequence; D000818:Animals; D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism*; D000943:Antigens, Differentiation / Q000235:genetics / Q000378:metabolism*; D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D001665:Binding Sites; D018106:CD28 Antigens / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D060908:CTLA-4 Antigen; D051379:Mice; D018345:Mice, Knockout; D008969:Molecular Sequence Data; D016415:Sequence Alignment; D017386:Sequence Homology, Amino Acid; D015996:Survival Rate
D048868:Adaptor Proteins, Signal Transducing; D015703:Antigens, CD; D000943:Antigens, Differentiation; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; C402726:Sh2d2a protein, mouse
Science. 1993 Jul 30;261(5121):609-12
7688139
Nat Immunol. 2004 Apr;5(4):435-42
15004555
Nature. 1994 May 26;369(6478):327-9
8183372
Eur J Immunol. 1995 Apr;25(4):1044-50
7737275
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8891-5
7568038
Science. 1995 Nov 10;270(5238):985-8
7481803
Immunity. 1995 Nov;3(5):541-7
7584144
J Biol Chem. 1996 Apr 19;271(16):9403-9
8621607
J Exp Med. 1996 Sep 1;184(3):931-43
9064353
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9296-301
9256476
Eur J Immunol. 1997 Aug;27(8):1887-92
9295023
J Immunol. 1997 Oct 1;159(7):3220-9
9317120
Immunity. 1997 Nov;7(5):619-28
9390686
J Biol Chem. 1998 Jan 2;273(1):296-301
9417079
J Biol Chem. 1998 Aug 14;273(33):21194-202
9694876
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8603-8
10411922
J Exp Med. 1999 Aug 2;190(3):375-84
10430626
J Immunol. 1999 Nov 1;163(9):5029-38
10528208
Nat Immunol. 2005 Feb;6(2):152-62
15640801
J Exp Med. 2006 Sep 4;203(9):2121-33
16908623
Immunity. 2000 Apr;12(4):431-40
10795741
J Immunol. 2000 Jun 1;164(11):5805-14
10820259
J Immunol. 2001 Mar 15;166(6):3797-803
11238622
Nat Immunol. 2001 Apr;2(4):325-32
11276203
J Clin Invest. 2001 Apr;107(7):881-7
11285307
J Immunol. 2001 May 1;166(9):5331-5
11313368
Nat Immunol. 2002 Mar;3(3):259-64
11828322
Nat Rev Immunol. 2003 Jul;3(7):544-56
12876557
Nat Rev Immunol. 2003 Dec;3(12):939-51
14647476
J Exp Med. 1993 Nov 1;178(5):1701-12
8228817